On the traces of XPD: Cell cycle matters - untangling the genotype-phenotype relationship of XPD mutations

Cell Division

Volumn 5, Issue , 2010, Pages

  Cameroni, Elisabetta ^a   Stettler, Karin ^a   Suter, Beat ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MURINAE;

EID: 77956522540     PISSN: None     EISSN: 17471028     Source Type: Journal    
DOI: 10.1186/1747-1028-5-24     Document Type: Review

References (117)

1. Lehmann AR. The xeroderma pigmentosum group D (XPD) gene: one gene, two functions, three diseases. Genes Dev 2001, 15:15-23. 10.1101/gad.859501, 11156600.
2. Kraemer KH, Patronas NJ, Schiffmann R, Brooks BP, Tamura D, Digiovanna JJ. Xeroderma pigmentosum, trichothiodystrophy and Cockayne syndrome: a complex genotype-phenotype relationship. Neuroscience 2007, 145:1388-1396. 10.1016/j.neuroscience.2006.12.020, 2288663, 17276014.
3. Andressoo JO, Hoeijmakers JH, de WH. Nucleotide excision repair and its connection with cancer and ageing. Adv Exp Med Biol 2005, 570:45-83. full_text, 18727498.
4. Capell BC, Tlougan BE, Orlow SJ. From the rarest to the most common: insights from progeroid syndromes into skin cancer and aging. J Invest Dermatol 2009, 129:2340-2350. 10.1038/jid.2009.103, 19387478.
5. Navarro CL, Cau P, Levy N. Molecular bases of progeroid syndromes. Hum Mol Genet 2006, 15 Spec No 2:R151-R161. 10.1093/hmg/ddl214, 16987878.
6. Niedernhofer LJ. Tissue-specific accelerated aging in nucleotide excision repair deficiency. Mech Ageing Dev 2008, 129:408-415. 10.1016/j.mad.2008.04.010, 18538374.
7. Niedernhofer LJ. Tissue-specific accelerated aging in nucleotide excision repair deficiency. Mech Ageing Dev 2008, 129:408-415. 10.1016/j.mad.2008.04.010, 2518655, 18538374.
8. Kraemer KH, Lee MM, Scotto J. Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases. Arch Dermatol 1987, 123:241-250. 10.1001/archderm.123.2.241, 3545087.
9. Masutani C, Araki M, Yamada A, Kusumoto R, Nogimori T, Maekawa T, et al. Xeroderma pigmentosum variant (XP-V) correcting protein from HeLa cells has a thymine dimer bypass DNA polymerase activity. EMBO J 1999, 18:3491-3501. 10.1093/emboj/18.12.3491, 1171428, 10369688.
10. Taylor EM, Broughton BC, Botta E, Stefanini M, Sarasin A, Jaspers NG, et al. Xeroderma pigmentosum and trichothiodystrophy are associated with different mutations in the XPD (ERCC2) repair/transcription gene. Proc Natl Acad Sci USA 1997, 94:8658-8663. 10.1073/pnas.94.16.8658, 23065, 9238033.
11. Nouspikel T. Nucleotide excision repair and neurological diseases. DNA Repair (Amst) 2008, 7:1155-1167. 10.1016/j.dnarep.2008.03.015, 18456575.
12. van HA, Natarajan AT, Mayne LV, van Zeeland AA, Mullenders LH, Venema J. Deficient repair of the transcribed strand of active genes in Cockayne's syndrome cells. Nucleic Acids Res 1993, 21:5890-5895. 10.1093/nar/21.25.5890, 310470, 8290349.
13. Bohr VA, Sander M, Kraemer KH. Rare diseases provide rare insights into DNA repair pathways, TFIIH, aging and cancer center. DNA Repair (Amst) 2005, 4:293-302. 10.1016/j.dnarep.2004.09.010, 15678607.
14. Lehmann AR. DNA repair-deficient diseases, xeroderma pigmentosum, Cockayne syndrome and trichothiodystrophy. Biochimie 2003, 85:1101-1111. 10.1016/j.biochi.2003.09.010, 14726016.
15. Vermeulen W, Scott RJ, Rodgers S, Muller HJ, Cole J, Arlett CF, et al. Clinical heterogeneity within xeroderma pigmentosum associated with mutations in the DNA repair and transcription gene ERCC3. Am J Hum Genet 1994, 54:191-200. 1918172, 8304337.
16. Bergmann E, Egly JM. Trichothiodystrophy, a transcription syndrome. Trends Genet 2001, 17:279-286. 10.1016/S0168-9525(01)02280-6, 11335038.
17. Liang C, Kraemer KH, Morris A, Schiffmann R, Price VH, Menefee E, et al. Characterization of tiger-tail banding and hair shaft abnormalities in trichothiodystrophy. J Am Acad Dermatol 2005, 52:224-232. 10.1016/j.jaad.2004.09.013, 15692466.
18. Botta E, Nardo T, Broughton BC, Marinoni S, Lehmann AR, Stefanini M. Analysis of mutations in the XPD gene in Italian patients with trichothiodystrophy: site of mutation correlates with repair deficiency, but gene dosage appears to determine clinical severity. Am J Hum Genet 1998, 63:1036-1048. 10.1086/302063, 1377495, 9758621.
19. Stefanini M, Botta E, Lanzafame M, Orioli D. Trichothiodystrophy: From basic mechanisms to clinical implications. DNA Repair (Amst) 2009, 9:2-10.
20. Itin PH, Sarasin A, Pittelkow MR. Trichothiodystrophy: update on the sulfur-deficient brittle hair syndromes. J Am Acad Dermatol 2001, 44:891-920. 10.1067/mjd.2001.114294, 11369901.
21. Broughton BC, Berneburg M, Fawcett H, Taylor EM, Arlett CF, Nardo T, et al. Two individuals with features of both xeroderma pigmentosum and trichothiodystrophy highlight the complexity of the clinical outcomes of mutations in the XPD gene. Hum Mol Genet 2001, 10:2539-2547. 10.1093/hmg/10.22.2539, 11709541.
22. Graham JM, Anyane-Yeboa K, Raams A, Appeldoorn E, Kleijer WJ, Garritsen VH, et al. Cerebro-oculo-facio-skeletal syndrome with a nucleotide excision-repair defect and a mutated XPD gene, with prenatal diagnosis in a triplet pregnancy. Am J Hum Genet 2001, 69:291-300. 10.1086/321295, 1235303, 11443545.
23. Meira LB, Graham JM, Greenberg CR, Busch DB, Doughty AT, Ziffer DW, et al. Manitoba aboriginal kindred with original cerebro-oculo- facio-skeletal syndrome has a mutation in the Cockayne syndrome group B (CSB) gene. Am J Hum Genet 2000, 66:1221-1228. 10.1086/302867, 1288189, 10739753.
24. Adamczewski JP, Rossignol M, Tassan JP, Nigg EA, Moncollin V, Egly JM. MAT1, cdk7 and cyclin H form a kinase complex which is UV light-sensitive upon association with TFIIH. EMBO J 1996, 15:1877-1884. 450106, 8617234.
25. Rossignol M, Kolb-Cheynel I, Egly JM. Substrate specificity of the cdk-activating kinase (CAK) is altered upon association with TFIIH. EMBO J 1997, 16:1628-1637. 10.1093/emboj/16.7.1628, 1169767, 9130708.
26. Drapkin R, Le RG, Cho H, Akoulitchev S, Reinberg D. Human cyclin-dependent kinase-activating kinase exists in three distinct complexes. Proc Natl Acad Sci USA 1996, 93:6488-6493. 10.1073/pnas.93.13.6488, 39050, 8692842.
27. Larochelle S, Chen J, Knights R, Pandur J, Morcillo P, Erdjument-Bromage H, et al. T-loop phosphorylation stabilizes the CDK7-cyclin H-MAT1 complex in vivo and regulates its CTD kinase activity. EMBO J 2001, 20:3749-3759. 10.1093/emboj/20.14.3749, 125544, 11447116.
28. Ito S, Tan LJ, Andoh D, Narita T, Seki M, Hirano Y, et al. MMXD, a TFIIH-independent XPD-MMS19 protein complex involved in chromosome segregation. Mol Cell 2010, 39:632-640. 10.1016/j.molcel.2010.07.029, 20797633.
29. Marini F, Nardo T, Giannattasio M, Minuzzo M, Stefanini M, Plevani P, et al. DNA nucleotide excision repair-dependent signaling to checkpoint activation. Proc Natl Acad Sci USA 2006, 103:17325-17330. 10.1073/pnas.0605446103, 1859929, 17088560.
30. Glover-Cutter K, Larochelle S, Erickson B, Zhang C, Shokat K, Fisher RP, et al. TFIIH-associated Cdk7 kinase functions in phosphorylation of C-terminal domain Ser7 residues, promoter-proximal pausing, and termination by RNA polymerase II. Mol Cell Biol 2009, 29:5455-5464. 10.1128/MCB.00637-09, 2756882, 19667075.
31. Keriel A, Stary A, Sarasin A, Rochette-Egly C, Egly JM. XPD mutations prevent TFIIH-dependent transactivation by nuclear receptors and phosphorylation of RARalpha. Cell 2002, 109:125-135. 10.1016/S0092-8674(02)00692-X, 11955452.
32. Sano M, Izumi Y, Helenius K, Asakura M, Rossi DJ, Xie M, et al. Menage-a-trois 1 is critical for the transcriptional function of PPARgamma coactivator 1. Cell Metab 2007, 5:129-142. 10.1016/j.cmet.2007.01.003, 17276355.
33. Helenius K, Yang Y, Alasaari J, Makela TP. Mat1 inhibits peroxisome proliferator-activated receptor gamma-mediated adipocyte differentiation. Mol Cell Biol 2009, 29:315-323. 10.1128/MCB.00347-08, 2612500, 18981214.
34. Rossi DJ, Londesborough A, Korsisaari N, Pihlak A, Lehtonen E, Henkemeyer M, et al. Inability to enter S phase and defective RNA polymerase II CTD phosphorylation in mice lacking Mat1. EMBO J 2001, 20:2844-2856. 10.1093/emboj/20.11.2844, 125252, 11387217.
35. Coin F, Marinoni JC, Rodolfo C, Fribourg S, Pedrini AM, Egly JM. Mutations in the XPD helicase gene result in XP and TTD phenotypes, preventing interaction between XPD and the p44 subunit of TFIIH. Nat Genet 1998, 20:184-188. 10.1038/2491, 9771713.
36. Larochelle S, Batliner J, Gamble MJ, Barboza NM, Kraybill BC, Blethrow JD, et al. Dichotomous but stringent substrate selection by the dual-function Cdk7 complex revealed by chemical genetics. Nat Struct Mol Biol 2006, 13:55-62. 10.1038/nsmb1028, 16327805.
37. Chen J, Larochelle S, Li X, Suter B. Xpd/Ercc2 regulates CAK activity and mitotic progression. Nature 2003, 424:228-232. 10.1038/nature01746, 12853965.
38. Chen J, Suter B. Xpd, a structural bridge and a functional link. Cell Cycle 2003, 2:503-506. 10.4161/cc.2.6.558, 14504460.
39. Ito S, Kuraoka I, Chymkowitch P, Compe E, Takedachi A, Ishigami C, et al. XPG stabilizes TFIIH, allowing transactivation of nuclear receptors: implications for Cockayne syndrome in XP-G/CS patients. Mol Cell 2007, 26:231-243. 10.1016/j.molcel.2007.03.013, 17466625.
40. Arab HH, Wani G, Ray A, Shah ZI, Zhu Q, Wani AA. Dissociation of CAK from core TFIIH reveals a functional link between XP-G/CS and the TFIIH disassembly state. PLoS One 2010, 5:e11007. 10.1371/journal.pone.0011007, 2882387, 20543986.
41. Dubaele S, Proietti De SL, Bienstock RJ, Keriel A, Stefanini M, Van HB, et al. Basal transcription defect discriminates between xeroderma pigmentosum and trichothiodystrophy in XPD patients. Mol Cell 2003, 11:1635-1646. 10.1016/S1097-2765(03)00182-5, 12820975.
42. Fan L, Fuss JO, Cheng QJ, Arvai AS, Hammel M, Roberts VA, et al. XPD helicase structures and activities: insights into the cancer and aging phenotypes from XPD mutations. Cell 2008, 133:789-800. 10.1016/j.cell.2008.04.030, 18510924.
43. Aguilar-Fuentes J, Fregoso M, Herrera M, Reynaud E, Braun C, Egly JM, et al. p8/TTDA overexpression enhances UV-irradiation resistance and suppresses TFIIH mutations in a Drosophila trichothiodystrophy model. PLoS Genet 2008, 4:e1000253. 10.1371/journal.pgen.1000253, 2576456, 19008953.
44. Schultz P, Fribourg S, Poterszman A, Mallouh V, Moras D, Egly JM. Molecular structure of human TFIIH. Cell 2000, 102:599-607. 10.1016/S0092-8674(00)00082-9, 11007478.
45. Wolski SC, Kuper J, Hanzelmann P, Truglio JJ, Croteau DL, Van HB, et al. Crystal structure of the FeS cluster-containing nucleotide excision repair helicase XPD. PLoS Biol 2008, 6:e149. 10.1371/journal.pbio.0060149, 2435149, 18578568.
46. Singleton MR, Dillingham MS, Wigley DB. Structure and mechanism of helicases and nucleic acid translocases. Annu Rev Biochem 2007, 76:23-50. 10.1146/annurev.biochem.76.052305.115300, 17506634.
47. Balajee AS, Bohr VA. Genomic heterogeneity of nucleotide excision repair. Gene 2000, 250:15-30. 10.1016/S0378-1119(00)00172-4, 10854775.
48. Lindahl T, Wood RD. Quality control by DNA repair. Science 1999, 286:1897-1905. 10.1126/science.286.5446.1897, 10583946.
49. Reardon JT, Sancar A. Thermodynamic cooperativity and kinetic proofreading in DNA damage recognition and repair. Cell Cycle 2004, 3:141-144.
50. McKinnon PJ. DNA repair deficiency and neurological disease. Nat Rev Neurosci 2009, 10:100-112. 10.1038/nrn2559, 19145234.
51. Coin F, Oksenych V, Mocquet V, Groh S, Blattner C, Egly JM. Nucleotide excision repair driven by the dissociation of CAK from TFIIH. Mol Cell 2008, 31:9-20. 10.1016/j.molcel.2008.04.024, 18614043.
52. Sandrock B, Egly JM. A yeast four-hybrid system identifies Cdk-activating kinase as a regulator of the XPD helicase, a subunit of transcription factor IIH. J Biol Chem 2001, 276:35328-35333. 10.1074/jbc.M105570200, 11445587.
53. Tirode F, Busso D, Coin F, Egly JM. Reconstitution of the transcription factor TFIIH: assignment of functions for the three enzymatic subunits, XPB, XPD, and cdk7. Mol Cell 1999, 3:87-95. 10.1016/S1097-2765(00)80177-X, 10024882.
54. Makela TP, Parvin JD, Kim J, Huber LJ, Sharp PA, Weinberg RA. A kinase-deficient transcription factor TFIIH is functional in basal and activated transcription. Proc Natl Acad Sci USA 1995, 92:5174-5178. 10.1073/pnas.92.11.5174, 41871, 7761469.
55. Serizawa H, Conaway JW, Conaway RC. Phosphorylation of C-terminal domain of RNA polymerase II is not required in basal transcription. Nature 1993, 363:371-374. 10.1038/363371a0, 8497323.
56. Larochelle S, Pandur J, Fisher RP, Salz HK, Suter B. Cdk7 is essential for mitosis and for in vivo Cdk-activating kinase activity. Genes Dev 1998, 12:370-381. 10.1101/gad.12.3.370, 316490, 9450931.
57. Rahl PB, Lin CY, Seila AC, Flynn RA, McCuine S, Burge CB, et al. c-Myc regulates transcriptional pause release. Cell 2010, 141:432-445. 10.1016/j.cell.2010.03.030, 20434984.
58. Price DH. Regulation of RNA polymerase II elongation by c-Myc. Cell 2010, 141:399-400. 10.1016/j.cell.2010.04.016, 20434979.
59. Glover-Cutter K, Kim S, Espinosa J, Bentley DL. RNA polymerase II pauses and associates with pre-mRNA processing factors at both ends of genes. Nat Struct Mol Biol 2008, 15:71-78. 10.1038/nsmb1352, 2836588, 18157150.
60. Nechaev S, Adelman K. Promoter-proximal Pol II: when stalling speeds things up. Cell Cycle 2008, 7:1539-1544.
61. Schwartz BE, Larochelle S, Suter B, Lis JT. Cdk7 is required for full activation of Drosophila heat shock genes and RNA polymerase II phosphorylation in vivo. Mol Cell Biol 2003, 23:6876-6886. 10.1128/MCB.23.19.6876-6886.2003, 193928, 12972606.
62. Offman J, Jina N, Theron T, Pallas J, Hubank M, Lehmann A. Transcriptional changes in trichothiodystrophy cells. DNA Repair (Amst) 2008, 7:1364-1371. 10.1016/j.dnarep.2008.05.002, 18579452.
63. da Costa RM, Riou L, Paquola A, Menck CF, Sarasin A. Transcriptional profiles of unirradiated or UV-irradiated human cells expressing either the cancer-prone XPB/CS allele or the noncancer-prone XPB/TTD allele. Oncogene 2005, 24:1359-1374. 10.1038/sj.onc.1208288, 15608684.
64. Larochelle S, Merrick KA, Terret ME, Wohlbold L, Barboza NM, Zhang C, et al. Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells. Mol Cell 2007, 25:839-850. 10.1016/j.molcel.2007.02.003, 17386261.
65. Botta E, Nardo T, Lehmann AR, Egly JM, Pedrini AM, Stefanini M. Reduced level of the repair/transcription factor TFIIH in trichothiodystrophy. Hum Mol Genet 2002, 11:2919-2928. 10.1093/hmg/11.23.2919, 12393803.
66. Li X, Urwyler O, Suter B. Drosophila Xpd regulates Cdk7 localization, mitotic kinase activity, spindle dynamics, and chromosome segregation. PLoS Genet 2010, 6:e1000876. 10.1371/journal.pgen.1000876, 2837399, 20300654.
67. Woodbury EL, Morgan DO. Cdk and APC activities limit the spindle-stabilizing function of Fin1 to anaphase. Nat Cell Biol 2007, 9:106-112. 10.1038/ncb1523, 17173039.
68. Edgar BA. Cell cycle. Cell-cycle control in a developmental context. Curr Biol 1994, 4:522-524. 10.1016/S0960-9822(00)00113-5, 7922372.
69. Larochelle S, Merrick KA, Terret ME, Wohlbold L, Barboza NM, Zhang C, et al. Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells. Mol Cell 2007, 25:839-850. 10.1016/j.molcel.2007.02.003, 1858677, 17386261.
70. Edgar BA, Sprenger F, Duronio RJ, Leopold P, O'Farrell PH. Distinct molecular mechanism regulate cell cycle timing at successive stages of Drosophila embryogenesis. Genes Dev 1994, 8:440-452. 10.1101/gad.8.4.440, 7510257.
71. Ducommun B, Brambilla P, Felix MA, Franza BR, Karsenti E, Draetta G. cdc2 phosphorylation is required for its interaction with cyclin. EMBO J 1991, 10:3311-3319. 453057, 1833185.
72. Branzei D, Foiani M. Regulation of DNA repair throughout the cell cycle. Nat Rev Mol Cell Biol 2008, 9:297-308. 10.1038/nrm2351, 18285803.
73. Lukas J, Lukas C, Bartek J. Mammalian cell cycle checkpoints: signalling pathways and their organization in space and time. DNA Repair (Amst) 2004, 3:997-1007. 10.1016/j.dnarep.2004.03.006, 15279786.
74. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000, 408:433-439. 10.1038/35044005, 11100718.
75. Schumacher B, Garinis GA, Hoeijmakers JH. Age to survive: DNA damage and aging. Trends Genet 2008, 24:77-85. 10.1016/j.tig.2007.11.004, 18192065.
76. Wu X, Shell SM, Yang Z, Zou Y. Phosphorylation of nucleotide excision repair factor xeroderma pigmentosum group A by ataxia telangiectasia mutated and Rad3-related-dependent checkpoint pathway promotes cell survival in response to UV irradiation. Cancer Res 2006, 66:2997-3005. 10.1158/0008-5472.CAN-05-3403, 1450106, 16540648.
77. Hwang BJ, Ford JM, Hanawalt PC, Chu G. Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genomic repair. Proc Natl Acad Sci USA 1999, 96:424-428. 10.1073/pnas.96.2.424, 15152, 9892649.
78. Wang XW, Yeh H, Schaeffer L, Roy R, Moncollin V, Egly JM, et al. p53 modulation of TFIIH-associated nucleotide excision repair activity. Nat Genet 1995, 10:188-195. 10.1038/ng0695-188, 7663514.
79. Wang XW, Vermeulen W, Coursen JD, Gibson M, Lupold SE, Forrester K, et al. The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev 1996, 10:1219-1232. 10.1101/gad.10.10.1219, 8675009.
80. Ko LJ, Shieh SY, Chen X, Jayaraman L, Tamai K, Taya Y, et al. p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner. Mol Cell Biol 1997, 17:7220-7229. 232579, 9372954.
81. Weber A, Liu J, Collins I, Levens D. TFIIH operates through an expanded proximal promoter to fine-tune c-myc expression. Mol Cell Biol 2005, 25:147-161. 10.1128/MCB.25.1.147-161.2005, 538784, 15601838.
82. Liu J, Akoulitchev S, Weber A, Ge H, Chuikov S, Libutti D, et al. Defective interplay of activators and repressors with TFIH in xeroderma pigmentosum. Cell 2001, 104:353-363. 10.1016/S0092-8674(01)00223-9, 11239393.
83. Amati B, Frank SR, Donjerkovic D, Taubert S. Function of the c-Myc oncoprotein in chromatin remodeling and transcription. Biochim Biophys Acta 2001, 1471:M135-M145.
84. Liu J, Kouzine F, Nie Z, Chung HJ, Elisha-Feil Z, Weber A, et al. The FUSE/FBP/FIR/TFIIH system is a molecular machine programming a pulse of c-myc expression. EMBO J 2006, 25:2119-2130. 10.1038/sj.emboj.7601101, 1462968, 16628215.
85. Vervoorts J, Luscher-Firzlaff J, Luscher B. The ins and outs of MYC regulation by posttranslational mechanisms. J Biol Chem 2006, 281:34725-34729. 10.1074/jbc.R600017200, 16987807.
86. Cotter TG. Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer 2009, 9:501-507. 10.1038/nrc2663, 19550425.
87. Cowling VH, Cole MD. HATs off to capping: a new mechanism for Myc. Cell Cycle 2007, 6:907-909. 10.4161/cc.6.21.4880, 17404507.
88. Cowling VH, Cole MD. The Myc transactivation domain promotes global phosphorylation of the RNA polymerase II carboxy-terminal domain independently of direct DNA binding. Mol Cell Biol 2007, 27:2059-2073. 10.1128/MCB.01828-06, 1820498, 17242204.
89. Mateyak MK, Obaya AJ, Sedivy JM. c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points. Mol Cell Biol 1999, 19:4672-4683. 84265, 10373516.
90. Staller P, Peukert K, Kiermaier A, Seoane J, Lukas J, Karsunky H, et al. Repression of p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol 2001, 3:392-399. 10.1038/35070076, 11283613.
91. Bootsma D, Hoeijmakers JH. DNA repair. Engagement with transcription. Nature 1993, 363:114-115. 10.1038/363114a0, 8483493.
92. de WH, de WJ, Andressoo JO, van Oostrom CT, Riis B, Weimann A, et al. Different effects of CSA and CSB deficiency on sensitivity to oxidative DNA damage. Mol Cell Biol 2004, 24:7941-7948. 10.1128/MCB.24.15.6850-6860.2004, 515046, 15340056.
93. Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell 2007, 130:223-233. 10.1016/j.cell.2007.07.003, 17662938.
94. Lehmann AR, Niimi A, Ogi T, Brown S, Sabbioneda S, Wing JF, et al. Translesion synthesis: Y-family polymerases and the polymerase switch. DNA Repair (Amst) 2007, 6:891-899. 10.1016/j.dnarep.2007.02.003, 17363342.
95. Boyle J, Ueda T, Oh KS, Imoto K, Tamura D, Jagdeo J, et al. Persistence of repair proteins at unrepaired DNA damage distinguishes diseases with ERCC2 (XPD) mutations: cancer-prone xeroderma pigmentosum vs. non-cancer-prone trichothiodystrophy. Hum Mutat 2008, 29:1194-1208. 10.1002/humu.20768, 18470933.
96. Berneburg M, Lowe JE, Nardo T, Araujo S, Fousteri MI, Green MH, et al. UV damage causes uncontrolled DNA breakage in cells from patients with combined features of XP-D and Cockayne syndrome. EMBO J 2000, 19:1157-1166. 10.1093/emboj/19.5.1157, 305654, 10698956.
97. Nowak MA, Komarova NL, Sengupta A, Jallepalli PV, Shih I, Vogelstein B, et al. The role of chromosomal instability in tumor initiation. Proc Natl Acad Sci USA 2002, 99:16226-16231. 10.1073/pnas.202617399, 138593, 12446840.
98. Garinis GA, van der Horst GT, Vijg J, Hoeijmakers JH. DNA damage and ageing: new-age ideas for an age-old problem. Nat Cell Biol 2008, 10:1241-1247. 10.1038/ncb1108-1241, 18978832.
99. Liu B, Wang J, Chan KM, Tjia WM, Deng W, Guan X, et al. Genomic instability in laminopathy-based premature aging. Nat Med 2005, 11:780-785. 10.1038/nm1266, 15980864.
100. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 2005, 120:513-522. 10.1016/j.cell.2005.02.003, 15734683.
101. Chen D, Riedl T, Washbrook E, Pace PE, Coombes RC, Egly JM, et al. Activation of estrogen receptor alpha by S118 phosphorylation involves a ligand-dependent interaction with TFIIH and participation of CDK7. Mol Cell 2000, 6:127-137. 10.1016/S1097-2765(00)00014-9, 10949034.
102. Mark M, Ghyselinck NB, Chambon P. Function of retinoic acid receptors during embryonic development. Nucl Recept Signal 2009, 7:e002. 2670431, 19381305.
103. Campbell RM, Digiovanna JJ. Skin cancer chemoprevention with systemic retinoids: an adjunct in the management of selected high-risk patients. Dermatol Ther 2006, 19:306-314. 10.1111/j.1529-8019.2006.00088.x, 17014486.
104. Benhamou S, Sarasin A. ERCC2/XPD gene polymorphisms and cancer risk. Mutagenesis 2002, 17:463-469. 10.1093/mutage/17.6.463, 12435843.
105. Compe E, Malerba M, Soler L, Marescaux J, Borrelli E, Egly JM. Neurological defects in trichothiodystrophy reveal a coactivator function of TFIIH. Nat Neurosci 2007, 10:1414-1422. 10.1038/nn1990, 17952069.
106. Moodycliffe AM, Nghiem D, Clydesdale G, Ullrich SE. Immune suppression and skin cancer development: regulation by NKT cells. Nat Immunol 2000, 1:521-525. 10.1038/82782, 11101875.
107. Lehmann AR, Norris PG. DNA repair and cancer: speculations based on studies with xeroderma pigmentosum, Cockayne's syndrome and trichothiodystrophy. Carcinogenesis 1989, 10:1353-1356. 10.1093/carcin/10.8.1353, 2752510.
108. Norris PG, Limb GA, Hamblin AS, Hawk JL. Impairment of natural-killer-cell activity in xeroderma pigmentosum. N Engl J Med 1988, 319:1668-1669. 10.1056/NEJM198812223192512, 3200282.
109. Gaspari AA, Fleisher TA, Kraemer KH. Impaired interferon production and natural killer cell activation in patients with the skin cancer-prone disorder, xeroderma pigmentosum. J Clin Invest 1993, 92:1135-1142. 10.1172/JCI116682, 288250, 7690772.
110. Mariani E, Facchini A, Honorati MC, Lalli E, Berardesca E, Ghetti P, et al. Immune defects in families and patients with xeroderma pigmentosum and trichothiodystrophy. Clin Exp Immunol 1992, 88:376-382. 10.1111/j.1365-2249.1992.tb06457.x, 1554504, 1535035.
111. Gasser S, Raulet D. The DNA damage response, immunity and cancer. Semin Cancer Biol 2006, 16:344-347. 10.1016/j.semcancer.2006.07.004, 16914325.
112. Andressoo JO, Mitchell JR, de WJ, Hoogstraten D, Volker M, Toussaint W, et al. An Xpd mouse model for the combined xeroderma pigmentosum/Cockayne syndrome exhibiting both cancer predisposition and segmental progeria. Cancer Cell 2006, 10:121-132. 10.1016/j.ccr.2006.05.027, 16904611.
113. de BJ, van SH, Berg RJ, Garssen J, de WJ, van Oostrum CT, et al. Mouse model for the DNA repair/basal transcription disorder trichothiodystrophy reveals cancer predisposition. Cancer Res 1999, 59:3489-3494.
114. Itoh M, Hayashi M, Shioda K, Minagawa M, Isa F, Tamagawa K, et al. Neurodegeneration in hereditary nucleotide repair disorders. Brain Dev 1999, 21:326-333. 10.1016/S0387-7604(99)00033-9, 10413020.
115. Brooks PJ, Cheng TF, Cooper L. Do all of the neurologic diseases in patients with DNA repair gene mutations result from the accumulation of DNA damage?. DNA Repair (Amst) 2008, 7:834-848. 10.1016/j.dnarep.2008.01.017, 2408373, 18339586.
116. Anolik JH, Di Giovanna JJ, Gaspari AA. Effect of isotretinoin therapy on natural killer cell activity in patients with xeroderma pigmentosum. Br J Dermatol 1998, 138:236-241. 10.1046/j.1365-2133.1998.02067.x, 9602867.
117. Cleaver JE, Thompson LH, Richardson AS, States JC. A summary of mutations in the UV-sensitive disorders: xeroderma pigmentosum, Cockayne syndrome, and trichothiodystrophy. Hum Mutat 1999, 14:9-22. 10.1002/(SICI)1098-1004(1999)14:1<9::AID-HUMU2>3.0.CO;2-6, 10447254.